Medicare Part D spending on GLP-1 receptor agonists increased more than fivefold between 2019 and 2024, reaching $27.5 billion, driven by rapidly expanding indications, landmark cardiovascular and renal outcome trials, and growing recognition of these therapies' role in chronic disease management. For value-based care organizations operating under shared financial accountability, this trajectory demands structured, evidence-based guidance.
AAVBC’s Landscape and Utilization of GLP-1 Receptor Agonists in Value-Based Care equips clinicians and care teams with a comprehensive, CMS-aligned reference covering FDA-approved indications, agent-specific outcome data, brand-level differentiation, treatment positioning frameworks, and documentation standards that reflect true clinical complexity. Grounded in the 2025-2026 ADA Standards of Care and major cardiovascular and renal trials, this guide supports consistent, evidence-informed clinical decision-making, helping care teams deliver the right therapy to the right patients, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of GLP-1 RA utilization — moving far beyond quick-reference essentials. These guides provide an integrated review of financial implications, decision frameworks, target conditions, risk stratifications, sustainability, document requirements as well as billing and coding considerations. The Deep-Dives combine evidence-informed clinical guidance with practical operational tools to support a deeper understanding of the GLP-1 RA landscape and utilization, and provide care teams with the necessary strategies to thrive within a value-based framework.
Medicare Part D spending on GLP-1 receptor agonists increased more than fivefold between 2019 and 2024, reaching $27.5 billion, driven by rapidly expanding indications, landmark cardiovascular and renal outcome trials, and growing recognition of these therapies' role in chronic disease management. For value-based care organizations operating under shared financial accountability, this trajectory demands structured, evidence-based guidance.
AAVBC’s Landscape and Utilization of GLP-1 Receptor Agonists in Value-Based Care equips clinicians and care teams with a comprehensive, CMS-aligned reference covering FDA-approved indications, agent-specific outcome data, brand-level differentiation, treatment positioning frameworks, and documentation standards that reflect true clinical complexity. Grounded in the 2025-2026 ADA Standards of Care and major cardiovascular and renal trials, this guide supports consistent, evidence-informed clinical decision-making, helping care teams deliver the right therapy to the right patients, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of GLP-1 RA utilization — moving far beyond quick-reference essentials. These guides provide an integrated review of financial implications, decision frameworks, target conditions, risk stratifications, sustainability, document requirements as well as billing and coding considerations. The Deep-Dives combine evidence-informed clinical guidance with practical operational tools to support a deeper understanding of the GLP-1 RA landscape and utilization, and provide care teams with the necessary strategies to thrive within a value-based framework.
